Discover Svar AAV Immunogenicity Suite
Newsletter

Discover Svar AAV Immunogenicity Suite

Uncompromised safety assessment for your AAV gene therapy development

At Svar Life Science, we are dedicated to developing and delivering solutions that can contribute to the development of innovative therapies for optimal therapeutic outcomes and patient benefit.

We support scientists at the forefront of innovation in gene therapy treatments, with a unique immunogenicity suite tailored for risk assessment in adeno-associated virus (AAV)-mediated gene therapy development.

The Svar AAV Immunogenicity Suite enables more extensive and better-informed AAV immunogenicity assessment for therapeutics in development. Our assays support scientists throughout the AAV program development in making confident decisions, and demonstrate pre-clinical results that can better meet regulatory expectations.

 

 

Svar’s AAV Immunogenicity Suite is the first‑of‑its‑kind, equipped with dedicated complement-activation assays designed for the semi-quantitative detection of pathway-independent AAV‑induced complement activation. This is offered as fully custom-developed AAV Complement Activation assays, and in our most recent addition, the AAV9-induced complement activation ELISA assay.

With tailored NAb, TAb, and complement-activation assays, the Svar AAV Immunogenicity Suite elevates your immunogenicity testing capabilities, enabling a confident evaluation of immunological reactions to AAV therapies. Well-informed decision making and risk assessments contribute to ensuring success in your development process of AAV-mediated gene therapies.

 

Svar AAV Immunogenicity Suite

How the Svar AAV Immunogenicity Suite assists you:

  • Assess immunogenicity across AAV serotypes in gene therapy programs.
  • Enable precise, efficient, and routine monitoring of anti-AAV immune reactions throughout development.
  • Strengthen risk assessment capabilities through functional evaluation of pathway-independent, AAV-mediated complement activation.
  • Identify and characterize complement-related immune reactions, including sample-to-sample variability in response.
  • Provide insights to support clinical trial design, improving the understanding of your vectors’ immunogenicity profile to reduce risk while safeguarding efficacy.
  • Customizable for any AAV serotype providing access to an extended immunogenicity profile to better understand your therapeutic, no matter what AAV capsid you choose.
  • Evaluate the impact of manufacturing processes and lot-specific variables on AAV-induced complement activation potential.
  • Enhance characterization of critical quality attributes (CQAs) by comparing capsids, batches, and process changes.
  • Support manufacturing comparability and batch-to-batch comparability, for consistent product quality.

Full customization to meet your development demands

Through Svar CRO Services’ extensive expertise, we offer fully customized development of dedicated assays for the characterization of AAV-induced immune response.

Svar's custom capabilities include:

  • AAV Total Antibody (TAb). Customizable for any capsid, adaptable to any AAV serotype, hybrid, or chimeric vector for next-gen development.
  • AAV NAb Reporter Gene Assays. Customizable for any capsid, both traditional and recombinant. Serotype specific assays are available for AAV2, AAV5, AAV6, AAV8, AAV9 on-demand.
  • AAV Complement Activation ELISA. Customizable for any capsid. Accommodates both wild-type and novel AAV capsid variants, including engineered and chimeric forms. The novel, serotype specific, assay is now available for AAV9 on-demand.

Interested in requesting a custom AAV Complement kit? Get in touch with us today.


Contact Our Gene Therapy Team

Write us a message and a product specialist will get in touch